BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Allo-RevCAR01-T readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Allo-RevCAR01-T\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05949125-2919@assetmemo.bio
DTSTAMP:20261121T010151Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Allo-RevCAR01-T: Phase 1 readout est. (NCT05949125)
DESCRIPTION:Allo-RevCAR01-T\, phase 1\, Acute Myeloid Leukemia.\nStudy: Pha
 se 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positi
 ve Hematologic Malignancies (1b Dose Expansion)\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/allo-r
 evcar01-t#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05949125
URL:https://assetmemo.bio/drug/allo-revcar01-t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
